← board
RDHL
RedHill Biopharma Limiteddistress 5/10 · elevated risk$0.69-1%today-73% from 52w high
Lead: Traveler's Diarrhea
Revenue
pre-revenue
Liquidity
$16M
Runway
1.7 yrs
Shares 1y
0%
Price & events
-48.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-7.8%
1W
-18.5%
1M
-19.1%
3M
-48.5%
6M
-68.4%
1Y
-92.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $34.88B
- Volume
- 26.30K
- 52 Week Range
- $0.69 – $2.52
- Total Shares
- 50.92B
- Float Shares
- 4.20M
- Short %
- 0.52%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 3.54%
- RVOL
- 0.08x
- Beta
- 4.97
Pipeline stages · 1 programs
Rifamycin SV-MMX, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06 | Phase 2 | Rifamycin SV-MMX, Placebo | Traveler's Diarrhea | 142 | unknown |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Traveler's Diarrhea
- none identified
Recent news
- 2026-07-14RedHill Biopharma Ltd. SEC Filing (Jul 14, 2026) - Stock Titan
- 2026-07-07Redhill Biopharma (RDHL) Bounces 3.42%: Key Levels to Watch - Cash Flow Strong Stocks - dars.gov.et
- 2026-06-22Form 6K RedHill Biopharma Ltd. For: 22 June By Investing.com - Investing.com Canada
- 2026-06-18RedHill Biopharma Announces Up To $19.4 Million Private Placement - PR Newswire
- 2026-06-09RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation - PR Newswire
- 2026-06-08RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo - The Malaysian Reserve
- 2026-06-03RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak | Corporate - EQS News
- 2026-06-02RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.